EMC
MCID: EPT010
MIFTS: 51

Epithelial-Myoepithelial Carcinoma (EMC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Epithelial-Myoepithelial Carcinoma

MalaCards integrated aliases for Epithelial-Myoepithelial Carcinoma:

Name: Epithelial-Myoepithelial Carcinoma 11 19 75 14 71
Clear Cell Adenoma 19 71
Epithelial Myoepithelial Carcinoma 19
Glycogen-Rich Adenocarcinoma 19
Monomorphic Clear Cell Tumor 19
Adenocarcinoma, Clear Cell 71
Glycogen-Rich Adenoma 19
Tubular Solid Adenoma 19
Adenomyo-Epithelioma 19
Clear Cell Carcinoma 19
Emc 19

Classifications:



External Ids:

Disease Ontology 11 DOID:5309
NCIt 49 C4199
SNOMED-CT 68 189722008
UMLS 71 C0206681 C0334315 C0334392

Summaries for Epithelial-Myoepithelial Carcinoma

GARD: 19 A malignant neoplasm which occurs mostly in the major salivary glands (most frequently in the parotid gland), but also in the minor salivary glands of the oral mucosa and the tracheobronchial tree. It is characterized by the presence of ductal structures which are lined by an inner layer of cuboidal epithelial-type cells and an outer layer of myoepithelial cells with clear or eosinophilic cytoplasm.

MalaCards based summary: Epithelial-Myoepithelial Carcinoma, also known as clear cell adenoma, is related to thymus clear cell carcinoma and lung clear cell carcinoma. An important gene associated with Epithelial-Myoepithelial Carcinoma is MAML2 (Mastermind Like Transcriptional Coactivator 2). The drugs Lenograstim and Rucaparib have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, ovary and lymph node, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Wikipedia: 75 Epithelial-myoepithelial carcinoma (EMCa) is a rare malignant tumour that typically arises in a salivary... more...

Related Diseases for Epithelial-Myoepithelial Carcinoma

Diseases related to Epithelial-Myoepithelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 thymus clear cell carcinoma 32.5 KIT EWSR1
2 lung clear cell carcinoma 32.4 KRT7 KRT5
3 chondrosarcoma, extraskeletal myxoid 31.9 SOX10 PLAG1 KIT EWSR1
4 trachea carcinoma 30.7 KRT7 KRT5
5 myoepithelioma 30.7 PLAG1 KRT14 EWSR1
6 mucoepidermoid carcinoma 30.7 MAML2 KRT7 KRT14 CRTC1
7 aggressive digital papillary adenocarcinoma 30.5 MAML2 KRT7
8 adenoid cystic carcinoma 30.4 NTRK3 NFIB KRT7 KRT14 KIT
9 myoepithelial carcinoma 30.4 SOX10 PLAG1 NFIB MAML2 KRT7 KRT5
10 thymic carcinoma 30.4 KRT7 KRT5 KIT
11 lacrimal gland carcinoma 30.3 PIP NFIB KRT7
12 breast adenomyoepithelioma 30.3 PLAG1 KRT7 KRT5 KRT14
13 papilloma 30.3 KRT7 KRT5 KRT14
14 breast ductal carcinoma 30.2 PIP KRT7 KRT5 KRT14
15 verrucous carcinoma 30.2 KRT5 KRT14
16 mixed germ cell cancer 30.2 KRT7 KIT
17 mixed cell type cancer 30.2 PLAG1 KRT7 KRT5 KIT
18 wilms tumor 1 30.1 KRT7 KRT5 KIT EWSR1
19 sebaceous adenocarcinoma 30.1 PIP KRT7 KRT5 KRT14
20 papillary adenocarcinoma 30.1 PIP KRT7 KRT5
21 lung giant cell carcinoma 30.1 KRT7 KRT5
22 glycogen-rich carcinoma 30.0 PIP KRT14
23 eccrine papillary adenocarcinoma 30.0 PIP KRT5
24 parotid gland cancer 30.0 NTRK3 MAML2 ETV6
25 perivascular epithelioid cell tumor 30.0 KIT ANO1
26 adenomatoid tumor 29.9 KRT7 KRT5
27 thymus cancer 29.9 KRT7 KRT5 KIT
28 breast metaplastic carcinoma 29.9 MAML2 KRT7 KRT5 KRT14 CRTC1
29 hidrocystoma 29.8 PIP KRT7
30 necrotizing sialometaplasia 29.7 PLAG1 MAML2 KRT7 KRT5 CRTC1
31 clear cell sarcoma 29.7 SOX10 KIT EWSR1
32 papillary cystadenocarcinoma 29.7 PIP MAML2 KRT7 CRTC1
33 anal canal carcinoma 29.7 PIP KRT7 KRT5
34 basal cell carcinoma 29.7 PIP KRT7 KRT5 KRT14
35 pleomorphic adenoma carcinoma 29.6 PLAG1 NTRK3 NFIB MAML2 ETV6 CRTC3
36 ductal carcinoma in situ 29.6 PIP KRT5 KRT14
37 mature teratoma 29.6 KRT7 KIT
38 neurilemmoma 29.6 SOX10 KIT ANO1
39 nephroma 29.6 NTRK3 KIT ETV6
40 fibrosarcoma 29.5 NTRK3 KIT EWSR1 ETV6
41 vascular cancer 29.5 KRT7 KIT EWSR1 ANO1
42 apocrine adenocarcinoma 29.5 PIP KRT7 KRT5 KRT14
43 acinar cell carcinoma 29.4 NTRK3 NFIB MAML2 KRT7 ETV6 CRTC1
44 paraganglioma 29.3 SOX10 NTRK3 KRT7 KIT
45 clear cell hidradenoma 29.2 PIP MAML2 KRT7 KRT5 CRTC3 CRTC1
46 spiradenoma 28.9 SOX10 PIP NTRK3 NFIB KRT7 KRT5
47 mesenchymal cell neoplasm 28.9 NTRK3 KIT EWSR1 ETV6 ANO1
48 gastrointestinal stromal tumor 28.8 SOX10 NTRK3 KIT EWSR1 ETV6 ANO1
49 mixed lacrimal gland cancer 28.5 SOX10 PLAG1 PIP NTRK3 KRT7 ETV6
50 salivary gland carcinoma 26.9 SOX10 PLAG1 PIP NTRK3 NFIB MAML2

Graphical network of the top 20 diseases related to Epithelial-Myoepithelial Carcinoma:



Diseases related to Epithelial-Myoepithelial Carcinoma

Symptoms & Phenotypes for Epithelial-Myoepithelial Carcinoma

MGI Mouse Phenotypes related to Epithelial-Myoepithelial Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.93 ANO1 CRTC1 CRTC3 ETV6 EWSR1 KIT
2 endocrine/exocrine gland MP:0005379 9.61 CRTC1 ETV6 EWSR1 KIT KRT14 NFIB
3 digestive/alimentary MP:0005381 9.23 ANO1 ETV6 KIT KRT14 KRT5 NFIB

Drugs & Therapeutics for Epithelial-Myoepithelial Carcinoma

Drugs for Epithelial-Myoepithelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
3
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60699 60700
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
5
Olaparib Approved Phase 3 763113-22-0 23725625
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
8
Metformin Approved Phase 2, Phase 3 1115-70-4, 657-24-9 4091
9
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
10
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
11
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
12
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
13
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
14
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
15
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
16
Cediranib Investigational Phase 3 288383-20-0 9933475
17
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
18
Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
19 Carotenoids Phase 3
20 Adjuvants, Immunologic Phase 3
21 Immunoglobulins, Intravenous Phase 2, Phase 3
22 Anti-Bacterial Agents Phase 3
23 topoisomerase I inhibitors Phase 2, Phase 3
24 Immunoglobulin G Phase 2, Phase 3
25 Antimitotic Agents Phase 3
26 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
27 Tubulin Modulators Phase 3
28 Antibodies, Monoclonal Phase 2, Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Liposomal doxorubicin Phase 3
31 Immunologic Factors Phase 2, Phase 3
32 Protein Kinase Inhibitors Phase 3
33 Angiogenesis Inhibitors Phase 2, Phase 3
34 Antiviral Agents Phase 3
35 Anti-Infective Agents Phase 3
36 Antimetabolites Phase 3
37 Immunosuppressive Agents Phase 3
38 Endothelial Growth Factors Phase 2, Phase 3
39 Mitogens Phase 2, Phase 3
40 Hypoglycemic Agents Phase 2, Phase 3
41 Taxane Phase 3 108169
42 Albumin-Bound Paclitaxel Phase 3
43 Tin Fluorides Phase 3
44
Vinblastine Approved Phase 2 865-21-4 241903 13342
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
47
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
48
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
49
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Unknown status NCT00807768 Phase 3 Carboplatin;Paclitaxel
2 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Unknown status NCT00719303 Phase 3
3 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
5 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Completed NCT00951496 Phase 3 Carboplatin;Cisplatin;Paclitaxel
6 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients Recruiting NCT04227522 Phase 3 Rucaparib;Placebos
7 Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy Recruiting NCT04575935 Phase 3 Chemotherapy
8 A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) Recruiting NCT05281471 Phase 3 Platinum chemotherapy: carboplatin (preferred) or cisplatin;Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;Bevacizumab (or biosimilar)
9 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Active, not recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
10 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
11 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
12 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
13 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
14 A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
15 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
16 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Active, not recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
17 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Active, not recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
18 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Active, not recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
19 A Phase III Randomized, Open Label Study of A Phase III Randomized, Open Label Study of NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus) Not yet recruiting NCT05460000 Phase 3 3 cycles chemotherapy instead of 6 cycles chemotherapy;6 cycles chemotherapy
20 Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study Unknown status NCT00226798 Phase 2 Capecitabine (Xeloda)
21 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA) Unknown status NCT03405454 Phase 2 durvalumab;standard chemotherapy
22 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Unknown status NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
23 Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas Completed NCT01914510 Phase 2 ENMD-2076
24 A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
25 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
26 A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
27 A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
28 A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma Completed NCT01097746 Phase 2 Carboplatin;Paclitaxel
29 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
30 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
31 A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01011933 Phase 2 Selumetinib
32 A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01132820 Phase 2 Cediranib Maleate
33 A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma Completed NCT00979992 Phase 2 Sunitinib Malate
34 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
35 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
36 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
37 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
38 A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02853318 Phase 2 Cyclophosphamide
39 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
40 A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
41 A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT02923739 Phase 2 Paclitaxel
42 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
43 A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
44 A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
45 Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study) Completed NCT03066427 Phase 2 Sunitinib
46 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
47 A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab Recruiting NCT04739800 Phase 2 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
48 Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
49 A Phase II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of CYH33, a Selective PI3Kα Inhibitor in Patients With Recurrent/Persistent Ovary, Fallopian Tube or Primary Peritoneal Clear Cell Carcinoma Recruiting NCT05043922 Phase 2 CYH33
50 Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma Recruiting NCT04735861 Phase 2 Sintilimab;Bevacizumab Biosimilar IBI305

Search NIH Clinical Center for Epithelial-Myoepithelial Carcinoma

Genetic Tests for Epithelial-Myoepithelial Carcinoma

Anatomical Context for Epithelial-Myoepithelial Carcinoma

Organs/tissues related to Epithelial-Myoepithelial Carcinoma:

MalaCards : Salivary Gland, Ovary, Lymph Node, Kidney, Cervix, Uterus, Breast

Publications for Epithelial-Myoepithelial Carcinoma

Articles related to Epithelial-Myoepithelial Carcinoma:

(show top 50) (show all 5012)
# Title Authors PMID Year
1
Multi-omics data fusion using adaptive GTO guided Non-negative matrix factorization for cancer subtype discovery. 62
36434961 2023
2
Prognostic and immunological role of FCER1G in pan-cancer. 62
36332324 2022
3
Pan-cancer analysis identifies the immunological and prognostic role of PAK4. 62
36470541 2022
4
Kidney in VHL disease: Early clear cell proliferation occurs in the distal tubular system. 62
36321775 2022
5
Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. 62
36028785 2022
6
Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma. 62
35389815 2022
7
Retraction Notice to: Oncogenic miR-27a delivered by exosomes binds to SFRP1 and promotes angiogenesis in renal clear cell carcinoma. 62
36381586 2022
8
RAKAT with ex situ tumorectomies: a new mini-invasive strategy for multiples and complex renal clear-cell carcinoma to avoid radical nephrectomy? 62
36374314 2022
9
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice. 62
35916971 2022
10
The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas. 62
35507079 2022
11
A rare case of epithelial-myoepithelial carcinoma arising ex pleomorphic adenoma of the lacrimal gland: case report and review of the literature. 62
36351193 2022
12
Refractory epithelial-myoepithelial carcinoma with pathological transformation in salivary gland: A case report. 62
36428138 2022
13
Female patient's outcome of primary bladder clear cell carcinoma managed with radical cystectomy:A case report. 62
36072282 2022
14
[Salivary gland tumors-an overview : Advances in molecular characterization: Part I]. 62
36227346 2022
15
Robot-assisted ipsilateral partial nephrectomy with distal ureterectomy for synchronous renal and ureteric tumors-a case report. 62
36437423 2022
16
Transoral robotic surgery for parapharyngeal carcinoma ex-pleomorphic adenoma: A case report. 62
35945155 2022
17
Whole-tumor ADC histogram analysis for differentiating endometriosis-related tumors: seromucinous borderline tumor, clear cell carcinoma and endometrioid carcinoma. 62
36401131 2022
18
Primary pulmonary hyalinizing clear cell carcinoma with pseudopapillary structures and abundant cysts filled with mucus. 62
36435095 2022
19
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery. 62
36416131 2022
20
Robot-Assisted Partial Nephrectomy with a New Robotic Surgical System: Feasibility and Perioperative Outcomes. 62
35838131 2022
21
MYPT1 inhibits the metastasis of renal clear cell carcinoma via the MAPK8/N-cadherin pathway. 62
36106411 2022
22
Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma. 62
36428521 2022
23
Systematic analysis of expression profiles and prognostic significance for MMDS-related iron-sulfur proteins in renal clear cell carcinoma. 62
36385109 2022
24
LINC00472 inhibits cell migration by enhancing intercellular adhesion and regulates H3K27ac level via interacting with P300 in renal clear cell carcinoma. 62
36371410 2022
25
Machine learning based identification of hub genes in renal clear cell carcinoma using multi-omics data. 62
36179770 2022
26
Identification and Validation of UPF1 as a Novel Prognostic Biomarker in Renal Clear Cell Carcinoma. 62
36421841 2022
27
Novel Retroperitoneal Neovascularity Scoring System in Renal Cell Carcinoma Tumor Staging. 62
36367194 2022
28
The Prognosis and Immune Microenvironment Related Factor Interleukin-23 in Clear Cell Renal Cell Carcinoma: A Radiological Investigation. 62
34739724 2022
29
Tat-hspb1 Suppresses Clear Cell Renal Cell Carcinoma (ccRCC) Growth via Lysosomal Membrane Permeabilization. 62
36428802 2022
30
LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway. 62
36429034 2022
31
Contemporary Drug Therapy for Renal Cell Carcinoma- Evidence Accumulation and Histological Implications in Treatment Strategy. 62
36359359 2022
32
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. 62
36333181 2022
33
Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. 62
36323715 2022
34
Prediction of pathological staging and grading of renal clear cell carcinoma based on deep learning algorithms. 62
36396624 2022
35
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation. 62
36368707 2022
36
Discovery of pathway-independent protein signatures associated with clinical outcome in human cancer cohorts. 62
36369472 2022
37
Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer In Silico Analysis. 62
36288884 2022
38
The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk. 62
36451132 2022
39
Leucine zipper protein 2 associates with prognosis and epigenetic modification in patients with renal clear cell carcinoma. 62
36379756 2022
40
MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis. 62
36354374 2022
41
Minimally-Invasive Radical Nephrectomy and Left-Sided Level II Caval Thrombectomy: a New Combined Technique. 62
36436673 2022
42
Laparoscopic systemic restaging surgery for women with unexpected uterine malignancy. 62
36414231 2022
43
Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer. 62
36208860 2022
44
Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (KGOG 3047). 62
35666535 2022
45
N6-methyladenosine long non-coding RNAs reveal novel tool to implicate overall survival and immune microenvironment in renal clear cell carcinoma. 62
36205842 2022
46
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. 62
36333148 2022
47
Organophosphate flame retardant TDCPP: A risk factor for renal cancer? 62
35764118 2022
48
Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte-associated genes. 62
35373928 2022
49
Comprehensive analysis of MFN2 as a prognostic biomarker associated with immune cell infiltration in renal clear cell carcinoma. 62
36007389 2022
50
Assessing the Vulnerability of Cancer Patients for COVID-19. 62
36237732 2022

Variations for Epithelial-Myoepithelial Carcinoma

Cosmic variations for Epithelial-Myoepithelial Carcinoma:

8 (show top 50) (show all 2075)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM145017479 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 10
2 COSM144087035 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 10
3 COSM93183448 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 10
4 COSM111758374 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 10
5 COSM122271391 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 10
6 COSM143156731 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Y61C 17:7674872-7674872 10
7 COSM144650895 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 10
8 COSM106053037 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 10
9 COSM144310046 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.542A>G p.Y181C 17:7674872-7674872 10
10 COSM121875754 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.263A>G p.Y88C 17:7674872-7674872 10
11 COSM148933502 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.*225G>C p.? 3:179234302-179234302 10
12 COSM87133148 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.3145G>C p.G1049R 3:179234302-179234302 10
13 COSM87135928 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 10
14 COSM148936463 PIK3CA salivary gland,parotid,carcinoma,myoepithelial carcinoma c.331A>G p.K111E 3:179199156-179199156 10
15 COSM103028523 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 10
16 COSM98760930 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 10
17 COSM98832818 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.455T>A p.L152* 23:53217863-53217863 10
18 COSM98771857 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.332T>A p.L111* 23:53217863-53217863 10
19 COSM111443773 KDM5C salivary gland,parotid,carcinoma,myoepithelial carcinoma c.254T>A p.L85* 23:53217863-53217863 10
20 COSM105721394 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.182A>G p.Q61R 11:533874-533874 10
21 COSM112988925 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 10
22 COSM101951686 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 10
23 COSM91331243 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 10
24 COSM105721476 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 10
25 COSM101967342 HRAS salivary gland,parotid,carcinoma,myoepithelial carcinoma c.181C>A p.Q61K 11:533875-533875 10
26 COSM151592898 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
27 COSM149960989 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
28 COSM150962667 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
29 COSM151345966 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
30 COSM151492854 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
31 COSM146246972 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
32 COSM110182063 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
33 COSM151326946 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
34 COSM150312692 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
35 COSM102381853 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
36 COSM102453467 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
37 COSM150277642 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
38 COSM150815521 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
39 COSM150455095 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
40 COSM151309497 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
41 COSM150915108 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
42 COSM150144859 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
43 COSM151828150 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
44 COSM150092506 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.83T>C p.I28T 3:41224616-41224616 10
45 COSM105890802 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
46 COSM149483724 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
47 COSM111889541 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
48 COSM149388003 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
49 COSM111039211 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10
50 COSM150528161 CTNNB1 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.104T>C p.I35T 3:41224616-41224616 10

Expression for Epithelial-Myoepithelial Carcinoma

Search GEO for disease gene expression data for Epithelial-Myoepithelial Carcinoma.

Pathways for Epithelial-Myoepithelial Carcinoma

GO Terms for Epithelial-Myoepithelial Carcinoma

Biological processes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.43 KRT7 KRT5 KRT14
2 stem cell differentiation GO:0048863 9.02 SOX10 KRT14 KIT

Molecular functions related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cAMP response element binding protein binding GO:0008140 8.92 CRTC3 CRTC1

Sources for Epithelial-Myoepithelial Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....